{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Dongsic Choi"}, {"accession": "MS:1000589", "name": "contact email", "value": "choi.dongsic@mail.mcgill.ca"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Research Associate"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Janusz Rak"}, {"accession": "MS:1000589", "name": "contact email", "value": "janusz.rak@mcgill.ca"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Janusz Rak MD, PhD Jack Cole Chair in Pediatric Hematology/Oncology Professor, Department of Pediatrics McGill University The Research Institute of the McGill University Health Centre Montreal Children's Hospital 1001 Decarie Blvd, Office # E M1 2244 Montreal, Quebec, H4A 3J1 Phone: (514) 412-4400 ext-office: 76240; -lab: 76220; Fax (514) 412-4331"}]}], "datasetFiles": [{"accession": "PRIDE:0000407", "name": "Result file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373_EV_3.mzid.gz"}, {"accession": "PRIDE:0000409", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373_EV2.mzid_U373_EV2.MGF"}, {"accession": "PRIDE:0000409", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373_EV1.mzid_U373_EV1.MGF"}, {"accession": "PRIDE:0000407", "name": "Result file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373_EV_2.mzid.gz"}, {"accession": "PRIDE:0000409", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373EV2 (U373_EV2).mzid_U373EV2_(U373_EV2).MGF"}, {"accession": "PRIDE:0000407", "name": "Result file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373vIII_EV_3.mzid.gz"}, {"accession": "PRIDE:0000407", "name": "Result file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373vIII_EV_2.mzid.gz"}, {"accession": "PRIDE:0000409", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373EV1 (U373_EV1).mzid_U373EV1_(U373_EV1).MGF"}, {"accession": "PRIDE:0000407", "name": "Result file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373_EV_1.mzid.gz"}, {"accession": "PRIDE:0000409", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373_Control.mzid_U373_Control.MGF"}, {"accession": "PRIDE:0000407", "name": "Result file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373vIII_EV_1.mzid.gz"}, {"accession": "PRIDE:0000409", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373v3_02_05_2017.mzid_U373v3_02_05_2017.MGF"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373vIII_EV_2.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373_EV_1.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373vIII_EV_3.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373vIII_EV_1.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373_EV_2.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311/U373_EV_3.raw"}], "description": "Glioblastoma multiforme (GBM) is a highly aggressive and heterogeneous form of primary brain tumors, driven by a complex repertoire of oncogenic alterations, including the constitutively active epidermal growth factor receptor (EGFRvIII). EGFRvIII impacts both cell-intrinsic and non-cell autonomous aspects of GBM progression, including cell invasion, angiogenesis and modulation of the tumor microenvoiront, this is, at least in part, attributable to the release and intercellular trafficking of extracellular vesicles (EVs), heterogeneous membrane structures containing multiple bioactive macromolecules. Here we analyzed the impact of EGFRvIII on the profile of glioma EVs using a series of isogenic tumor cell lines, in which this oncogene exhibits a strong transforming activity. Thus, we observed that EGFRvIII expression alters several properties of glioma EVs, including their output and global protein composition. Using mass spectrometry, quantitative proteomic analysis and Gene Ontology terms filters, we observed that EVs released by EGFRVIII-transformed cells were enriched for extracellular exosome and focal adhesion related proteins. Among them, we validated the association of pro-invasive proteins (CD44, BSG, CD151) with EVs of EGFRvIII expressing cells, and down-regulation of exosomal markers (CD81 and CD82) in EVs of their indolent counterparts. Nano-flow cytometry revealed that the EV output from individual glioma cell lines was highly heterogeneous, such that only a fraction of EVs contained specific proteins such as EGFR, CD9, or others. Notably, cells expressing EGFRvIII released ample EVs double positive for CD44/BSG, and these proteins also co-localized in cellular filopodia. We also detected the expression of homophilic adhesion molecules and increased homologous EV uptake by EGFRvIII-positive glioma cells. These results suggest that oncogenic EGFRvIII reprograms the proteome of GBM-related EVs, a notion with considerable implications for their biological activity and properties relevant for development of EV-based cancer biomarkers.", "fullDatasetLinks": [{"accession": "PRIDE:0000411", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2018/07/PXD008311"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD008311"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD008311"}, {"accession": "MS:1001922", "name": "Digital Object Identifier (DOI)", "value": "10.6019/PXD008311"}], "instruments": [{"accession": "MS:1002416", "name": "Orbitrap Fusion"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "EGFRvIII, oncogene, extracellular vesicles, exosomes, invasion, heterogeneity, glioblastoma, glioma, cancer, nano-flow cytometry"}], "modifications": [{"accession": "UNIMOD:6", "name": "Carboxymethyl"}, {"accession": "UNIMOD:7", "name": "Deamidated"}, {"accession": "UNIMOD:35", "name": "Oxidation"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "30006486"}, {"accession": "PRIDE:0000400", "name": "Reference", "value": "Choi D, Montermini L, Kim DK, Meehan B, Roth FP, Rak J. The impact of oncogenic EGFRvIII on the proteome of extracellular vesicles released from glioblastoma cells. Mol Cell Proteomics. 2018"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "The impact of oncogenic EGFRvIII on the proteome of extracellular vesicles (exosomes) released from glioblastoma cells"}